Scientific publications

Scientific publications based on FranceCoag data. Select a title to read the abstract.

Tabele et al. : Life expectancy of people with hemophilia in France in 2022


Roques MA et al. : Navigating the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia: The Qualitative Phase of the TRANSHEMO Project


Nguyen A et al : Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project


Meunier S et al : Severe haemorrhages leading to a diagnosis of rare bleeding disorder occur at a very young age. A study from the FranceCoag network Haemophilia


Nguyen A et al : Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross-sectional study based on the FranceCoag registry


Resseguier N et al : Occupational integration of adults with severe haemophilia (INTHEMO): A study based on the FranceCoag registry


Saultier P et al: Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A


Rugeri L et al : Gynecological and obstetric outcome in the French cohort of women with Factor XIII deficiency


Bouttefroy S et al : Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort


Row C et al : Abnormal Bleeding Phenotype in Mild Hemophilia B Patients with the p.Ile112Thr Variation on the Gene for Factor IX


Calvez T et al : Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A


Volkers A et al : Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies


Iorio A et al : Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries


Resseguier N et al : Determinants of Adherence and Consequences of the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia (TRANSHEMO): Study Protocol for a Multicentric French National Observational Cross-Sectional Study


Doncarli A et al : FranceCoag: A 22-year Prospective Follow-Up of the National French Cohort of Patients With Inherited Bleeding Disorders


Calvez T et al : Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product


Meunier S et al : Use of clinical practice guidelines on long-term prophylaxis in severe hemophilia in France: a retrospective audit


Chambost H et al : Epidemiology of Hereditary Bleeding Disorders: Input of FranceCoag Network


Chambost H et al : Implementation of a hepatitis A prevention policy in haemophiliacs: results from the French cohort


Chambost H et al : What Factors Influence the Age at Diagnosis of Hemophilia? Results of the French Hemophilia Cohort


Gaboulaud V et al : Prevalence of IgG Antibodies to Human Parvovirus B19 in Haemophilia Children Treated With Recombinant Factor (F)VIII Only or With at Least One Plasma-Derived FVIII or FIX Concentrate: Results From the French Haemophilia Cohort


Calvez T et al : The French Haemophilia Cohort: Rationale and Organization of a Long-Term National Pharmacosurveillance System